Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy

被引:34
作者
Huang, W
De Gruttola, V
Fischl, M
Hammer, S
Richman, D
Havlir, D
Gulick, R
Squires, K
Mellors, J
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[2] Univ Miami, Sch Med, Dept Med, Miami, FL USA
[3] Columbia Univ, Coll Phys & Surg, Div Infect Dis, New York, NY USA
[4] Columbia Univ, Cornell Clin Trials Unit, New York, NY USA
[5] Univ Calif San Diego, Dept Vet Affairs Med Ctr, Dept Pathol, San Diego, CA 92103 USA
[6] Univ Calif San Diego, Dept Vet Affairs Med Ctr, Dept Med, San Diego, CA 92103 USA
[7] Univ So Calif, Los Angeles Cty Med Ctr, Rand Schrader Clin, Los Angeles, CA 90033 USA
[8] Univ Pittsburgh, Dept Vet Affairs Med Ctr, HIV AIDS Program, Pittsburgh, PA USA
关键词
D O I
10.1086/320192
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Early identification of treatment failure among human immunodeficiency virus (HIV) type 1-infected patients receiving antiretroviral therapy could enable clinicians to modify inadequate regimens and to improve treatment response. Clinical definitions of treatment failure, however, may not be ideally suited for this purpose. This study empirically characterizes the patterns of HIV-1 RNA response to antiretroviral therapy in patients in 4 AIDS clinical trials. The approach assumed 2 patterns of HIV-1 response: "on track," for eventual suppression to HIV-1 RNA levels below the limit of quantification, and "off track," for deviation from this response. The results of this on- or off-track classification generally agreed with the protocol-defined outcomes of virologic success and failure, thus validating these commonly used definitions. Overall, only a minority of patients went off track because of suboptimal HIV-1 RNA response by the first follow-up visit. Most patients who went off track did so at later time points and had sharp unexpected rebounds without prior indication of a suboptimal response.
引用
收藏
页码:1455 / 1465
页数:11
相关论文
共 23 条
[1]   Indinavir concentrations and antiviral effect [J].
Acosta, EP ;
Henry, K ;
Baken, L ;
Page, LM ;
Fletcher, CV .
PHARMACOTHERAPY, 1999, 19 (06) :708-712
[2]  
ACOSTA EP, 2000, 7 C RETR OPP INF SAN
[3]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]  
DeGruttola V, 2000, ANTIVIR THER, V5, P41
[6]   MAXIMUM LIKELIHOOD FROM INCOMPLETE DATA VIA EM ALGORITHM [J].
DEMPSTER, AP ;
LAIRD, NM ;
RUBIN, DB .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-METHODOLOGICAL, 1977, 39 (01) :1-38
[7]   Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy [J].
Descamps, D ;
Flandre, P ;
Calvez, V ;
Peytavin, G ;
Meiffredy, V ;
Collin, G ;
Delaugerre, C ;
Robert-Delmas, S ;
Bazin, B ;
Aboulker, JP ;
Pialoux, G ;
Raffi, F ;
Brun-Vézinet, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (02) :205-211
[8]  
Diggle PJ., 1996, Analysis of longitudinal data
[9]  
GARRAFFO R, 1999, 3 INT WORKSH HIV DRU, P75
[10]  
GULICK R, 2000, 7 C RETR OPP INF SAN